MNOV - MediciNova Inc Stock Price, Fair Value and News

1.43USD0.00 (0.00%)Market Closed

Market Summary

USD1.430.00

Market Closed

0.00%

MNOV Stock Price

View Fullscreen

MNOV RSI Chart

MNOV Valuation

Market Cap

70.1M

Price/Earnings (Trailing)

-8.34

Price/Sales (Trailing)

40.7

EV/EBITDA

-2.69

Price/Free Cashflow

-8.61

MNOV Price/Sales (Trailing)

MNOV Profitability

Operating Margin

100.00%

EBT Margin

-497.26%

Return on Equity

-14.05%

Return on Assets

-13.37%

Free Cashflow Yield

-11.61%

MNOV Fundamentals

MNOV Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-21.91%

Rev. Growth (Qtr)

-8.88%

MNOV Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

5.59%

Earnings Growth (Qtr)

-33.77%

Breaking Down MNOV Revenue

Last 7 days

-6.5%

Last 90 days

5.1%

Trailing 12 Months

-32.6%

How does MNOV drawdown profile look like?

MNOV Financial Health

Current Ratio

19.07

MNOV Investor Care

Buy Backs (1Y)

0.01%

Diluted EPS (TTM)

-0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	0	0	0
2023	1.3M	1.6M	1.8M	1.8M
2022	3.2M	2.4M	1.6M	809.7K
2021	7.4M	8.7M	9.9M	4.0M
2020	6.6M	7.0M	6.6M	6.2M
2019	1.7M	1.7M	1.8M	6.5M
2018	7.8M	5.7M	3.6M	1.5M
2017	2.6M	5.0M	7.5M	9.9M
2016	495.5K	383.5K	271.5K	159.5K
2015	2.9M	2.1M	1.4M	607.5K
2014	5.4M	4.8M	4.3M	3.7M
2013	3.4M	0	0	6.0M
2012	0	0	0	802.6K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MediciNova Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 28, 2022	nagao hideki	sold	-15,196	2.25	-6,754	-
Nov 22, 2022	nagao hideki	sold	-464	2.13	-218	-
Nov 21, 2022	nagao hideki	sold	-11,695	2.18	-5,365	-
Nov 17, 2022	nagao hideki	sold	-673	2.18	-309	-
Aug 23, 2021	matsuda kazuko	acquired	138,000	2.3	60,000	chief medical officer
Jul 09, 2021	iwaki yuichi	acquired	100,541	2.54	39,583	president and ceo
Jun 24, 2021	matsuda kazuko	acquired	256,622	2.49623	102,804	chief medical officer
May 19, 2021	obrien geoffrey	acquired	109,122	2.5191	43,318	vice president
Mar 11, 2021	nagao hideki	sold	-17,419	7.4	-2,354	-
Feb 25, 2021	iwaki yuichi	acquired	212,175	2.46	86,250	president and ceo

Which funds bought or sold MNOV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-19.39	-4,752	16,766	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-16.00	442	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	37,949	37,949	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-16,416	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-55.24	-	1,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-7,258	210,463	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-17.43	-11,015	43,570	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	30.15	3,149	15,355	-%
May 15, 2024	Essex Woodlands Management, Inc.	unchanged	-	-55,298	1,603,610	0.47%
May 15, 2024	Squarepoint Ops LLC	reduced	-1.94	-1,184	21,541	-%

Are Funds Buying or Selling MNOV?

Are funds buying MNOV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNOV

No. of Funds

Unveiling MediciNova Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 12, 2022	3d investment partners pte. ltd.	11.2%	5,502,047	SC 13D/A
Jul 12, 2021	blackrock inc.	2.3%	1,127,922	SC 13G/A
Jan 29, 2021	blackrock inc.	7.4%	3,313,971	SC 13G/A
Jan 21, 2021	3d investment partners pte. ltd.	11.3%	5,502,047	SC 13D
Feb 05, 2020	blackrock inc.	6.5%	2,835,590	SC 13G/A

Recent SEC filings of MediciNova Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 01, 2024	8-K	Current Report
Feb 15, 2024	10-K	Annual Report

Peers (Alternatives to MediciNova Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MediciNova Inc News

Latest updates

MediciNova Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-8.9%	397,510	436,265	437,934	451,420	509,046	427,304	253,755	91,275	45,638	-	37,500	-	4,000,000	5,863,904	3,313,194	762,483	412,692	5,569,048	288,643	307,574	304,245
Operating Expenses	25.9%	3,135,993	2,490,104	2,146,888	3,300,030	2,963,243	3,231,235	3,897,467	4,089,935	3,410,012	2,102,831	3,639,439	4,309,513	4,201,529	3,013,442	3,730,016	4,510,366	2,924,499	2,224,132	2,645,565	4,182,021	4,979,359
S&GA Expenses	-100.0%	-	839,326	1,352,182	1,564,295	1,486,567	1,218,611	1,443,264	1,524,966	1,298,016	325,819	1,550,821	1,782,390	2,056,255	1,216,265	1,492,139	2,311,330	1,673,754	395,295	1,494,750	2,716,509	3,345,481
R&D Expenses	-	1,700,000	-	-	-	1,400,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-6.5%	-4.96	-4.66	-7.69	-8.56	-10.96	-17.35	-6.25	-4.17	-3.13	-2.50	-1.40	-1.60	-	-	-	-	-	-	-	-	-
EBT Margin	-6.5%	-4.97	-4.67	-7.70	-8.57	-10.98	-17.37	-6.27	-4.18	-3.14	-2.51	-1.40	-1.60	-	-	-	-	-	-	-	-	-
Net Income	-33.8%	-2,754,518	-2,059,085	-723,107	-2,871,820	-2,917,504	-3,001,484	-3,652,184	-4,028,998	-3,386,417	-2,083,145	-3,579,167	-4,284,141	-187,799	-2,985,289	-3,703,820	-4,451,229	-2,713,559	-1,984,088	-2,378,504	-3,881,876	-4,697,190
Net Income Margin	-4.4%	-4.88	-4.67	-5.21	-7.58	-10.61	-17.38	-8.13	-5.40	-4.13	-2.51	-1.11	-1.29	-	-	-	-	-	-	-	-	-
Free Cashflow	-675.1%	-3,868,226	-499,038	-1,374,293	-2,383,016	-3,177,413	-4,007,044	-2,720,151	-2,455,968	-3,728,400	-3,638,966	-3,018,561	1,094,238	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-5.1%	63.00	66.00	68.00	69.00	71.00	74.00	78.00	81.00	84.00	87.00	92.00	94.00	96.00	75.00	77.00	76.00	77.00	79.00	78.00	77.00	79.00
Current Assets	-6.5%	48.00	51.00	53.00	54.00	56.00	59.00	53.00	66.00	69.00	72.00	76.00	79.00	81.00	61.00	63.00	61.00	62.00	64.00	63.00	62.00	64.00
Cash Equivalents	-7.6%	47.00	51.00	52.00	53.00	55.00	19.00	53.00	65.00	68.00	71.00	75.00	78.00	76.00	60.00	62.00	60.00	61.00	64.00	63.00	62.00	63.00
Net PPE	-11.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Liabilities	-21.3%	3.00	4.00	3.00	4.00	3.00	4.00	5.00	5.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00
Current Liabilities	-23.4%	3.00	3.00	3.00	3.00	3.00	3.00	5.00	4.00	3.00	3.00	4.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	1.00
Shareholder's Equity	-4.1%	60.00	62.00	65.00	65.00	68.00	70.00	73.00	77.00	80.00	84.00	86.00	89.00	92.00	71.00	74.00	71.00	73.00	75.00	74.00	73.00	75.00
Retained Earnings	-0.7%	-418	-415	-413	-412	-410	-407	-404	-400	-396	-393	-390	-387	-383	-382	-379	-376	-371	-369	-367	-364	-360
Additional Paid-In Capital	0.0%	478	478	478	478	478	477	477	477	477	477	478	477	476	454	454	447	445	444	441	438	436
Shares Outstanding	0%	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	49.00	48.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	109	-	-	-	118	-	-	-	197	-	-	-	227	-	-	-	393	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-675.1%	-3,868	-499	-1,371	-2,383	-3,177	-4,007	-2,720	-2,455	-3,728	-3,638	-3,015	1,127	-3,853	-1,949	-3,908	-2,090	-2,878	-2,404	-2,039	-1,652	-3,029
Share Based Compensation	190.7%	215	-237	219	326	403	129	158	275	81.00	-756	579	756	1,140	398	1,034	1,147	596	-803	374	1,843	2,700
Cashflow From Investing	-100.0%	-	22*	-2.74	-18.58	39,929	-30,005	-	-	-	-	-2.94	-	-	-32.70	-1.19	-10*	-2.59	-7.26	-	-2.06	-1.95
Cashflow From Financing	-	-	-	-	-	-	-	-	-	-	39.00	250	390	20,100	359	5,127	1,201	419	3,331	3,175	180	3,929

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MNOV Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research, development and patents	$ 1,781,869	$ 1,476,676
General and administrative	1,354,124	1,486,567
Total operating expenses	3,135,993	2,963,243
Operating loss	(3,135,993)	(2,963,243)
Interest income	397,510	509,046
Other expense	(16,035)	(463,307)
Net loss	$ (2,754,518)	$ (2,917,504)
Basic net loss per common share	$ (0.06)	$ (0.06)
Diluted net loss per common share	$ (0.06)	$ (0.06)
Shares used to compute basic net loss per common share	49,046,246	49,046,246
Shares used to compute diluted net loss per common share	49,046,246	49,046,246
Net loss	$ (2,754,518)	$ (2,917,504)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(8,892)	(1,542)
Comprehensive loss	$ (2,763,410)	$ (2,919,046)

MNOV Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 47,138,799	$ 50,999,442
Prepaid expenses and other current assets	724,796	174,938
Total current assets	47,863,595	51,174,380
Goodwill	9,600,240	9,600,240
In-process research and development	4,800,000	4,800,000
Property and equipment, net	40,384	45,800
Right-of-use asset	519,307	575,406
Other non-current assets	70,391	74,151
Total assets	62,893,917	66,269,977
Current liabilities:
Accounts payable	804,764	1,003,937
Accrued liabilities and other current liabilities	1,487,845	2,059,238
Operating lease liability	217,887	215,926
Total current liabilities	2,510,496	3,279,101
Deferred tax liability	201,792	201,792
Other non-current liabilities	351,185	410,660
Total liabilities	3,063,473	3,891,553
Commitments and contingencies (Note 4)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,046,246 and 49,046,246 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	49,046	49,046
Additional paid-in capital	478,364,591	478,149,161
Accumulated other comprehensive loss	(126,982)	(118,090)
Accumulated deficit	(418,456,211)	(415,701,693)
Total stockholders’ equity	59,830,444	62,378,424
Total liabilities and stockholders' equity	$ 62,893,917	$ 66,269,977

About MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

CEO	Dr. Yuichi Iwaki M.D., Ph.D.
WEBSITE	medicinova.com
INDUSTRY	Biotechnology
EMPLOYEES	13

MediciNova Inc Frequently Asked Questions

What is the ticker symbol for MediciNova Inc? What does MNOV stand for in stocks?

MNOV is the stock ticker symbol of MediciNova Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MediciNova Inc (MNOV)?

As of Fri May 17 2024, market cap of MediciNova Inc is 70.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNOV stock?

You can check MNOV's fair value in chart for subscribers.

What is the fair value of MNOV stock?

You can check MNOV's fair value in chart for subscribers. The fair value of MediciNova Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MediciNova Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MediciNova Inc a good stock to buy?

The fair value guage provides a quick view whether MNOV is over valued or under valued. Whether MediciNova Inc is cheap or expensive depends on the assumptions which impact MediciNova Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNOV.

What is MediciNova Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MNOV's PE ratio (Price to Earnings) is -8.34 and Price to Sales (PS) ratio is 40.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNOV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MediciNova Inc's stock?

In the past 10 years, MediciNova Inc has provided -0.025 (multiply by 100 for percentage) rate of return.